I wouldn't count on that happening right away. But within a year, yes, I think it's probable. A lot will depend on the results from the clinical trials.
The price rise we're seeing right now is driven by a lack of liquidity rather than by specific news. It's what I've been predicting on this MB for a while now as the most probable scenario given the chart. But in the end, the fundamentals are what matter, not the chart. There is always risk and outcomes of clinical trials are particularly high risk.
So no guarantees, but it looks like IPXL has good prospects. If you can afford to sit out a downturn due to disappointing news from the trials (not saying that will happen but you need to allow that it could), it may be worth your while to hang onto this one through 2011. You should decide now which way you'll go because price will overshoot then correct. If you want to exit, you should watch price momentum and place an optimistic buy order when it starts to inflect.
Due to the GSK deal, IPX066 has already generated $11.5M (upfront). The P III trial results are expected to be out in 2Q11 and be good. Thus, don't expect too much effects on PPS. NDA is expected to be filed in 4Q11. The PDUFA date would be in 3Q12. The PDUFA effect could be significant. However, it is the first time that Impax has the chance of having a branded drug, thus lack of experience may lead to some bumpers.